Goldman Sachs Group was initially given a neutral investment rating of 01011-HK, with a target price of HK $3.20 (equivalent to 13 times the price-to-earnings ratio for 11 years). He pointed out that Tailing is the largest supplier of comprehensive vaccines in the mainland, with annual sales growth of 136% in fiscal year 12 and an annual increase of 58% in fiscal year 11, but believes that the national health care reform policy still poses risks to its business prospects.

Tai Ling Pharmaceuticals fell 7.55% to HK $2.57.